Successes of cancer care distorted in mainstream media

Well you can't say that the mainstream media doesn't like an underdog.

According to research out of the University of Pennsylvania and published in Archives of Internal Medicine, when mainstream media outlets cover cancer, they overwhelmingly focus on the positives of a cancer treatment, clinical trial or novel medication by mentioning the patients who benefitted, while tending not to mention patient deaths in the same treatment or clinical trial. The end result is an extremely distorted view of cancer care.

The research involved 436 articles in major newspapers and magazines such as The New York Times and People. A mere 13 percent of the articles hedged the information they provided by including the fact that most aggressive treatments neither end in cure or lengthen survival times for patients, while a shocking 70 percent ignored the reality of side effects, either in the short term or the long term.

Palliation and end-of-life issues were almost non-existent, mentioned in just a couple of the articles, leading researchers to conclude that "These portrayals of cancer care in the news media may give patients an inappropriately optimistic view of cancer treatment, outcomes, and prognosis."

By Ross Bonander

Sources
- Archives of Internal Medicine
- MedPageToday

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap